Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive - A randomized controlled trial

Citation
Mc. Audet et al., Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive - A randomized controlled trial, J AM MED A, 285(18), 2001, pp. 2347-2354
Citations number
23
Categorie Soggetti
General & Internal Medicine","Medical Research General Topics
Journal title
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
ISSN journal
00987484 → ACNP
Volume
285
Issue
18
Year of publication
2001
Pages
2347 - 2354
Database
ISI
SICI code
0098-7484(20010509)285:18<2347:EOCEAC>2.0.ZU;2-X
Abstract
Context Oral contraceptive (OC) pills are effective, but poor compliance in creases rates of pregnancy during treatment. Objective To compare the contraceptive efficacy, cycle control, compliance, and safety of a transdermal contraceptive patch and an OC, Design Randomized, open-label, parallel-group trial conducted October 1997 to June 1999. Setting Forty-five clinics in the United States and Canada. Participants A total of 1417 healthy adult women of child-bearing potential . Interventions Participants were randomly assigned to receive a transdermal contraceptive patch (n=812) vs an OC (n=605) for 6 or 13 cycles. Patch trea tment consisted of application of 3 consecutive 7-day patches followed by 1 patch-free week. Main Outcome Measures Overall and method-failure Pearl Indexes (number of p regnancies/100 person-years of use) and life-table estimates of the probabi lity of pregnancy were calculated. Cycle control, compliance, patch adhesio n, and adverse events were also assessed. Results Overall and method-failure Pearl Indexes were numerically lower wit h the patch (1.24 and 0.99, respectively) vs the OC (2.18 and 1.25, respect ively); this difference was not statistically significant (P=.57 and .80, r espectively), The incidence of breakthrough bleeding and/or spotting was si gnificantly higher only in the first 2 cycles in the patch group, but the i ncidence of breakthrough bleeding alone was comparable between treatments i n all cycles. The mean proportion of participants' cycles with perfect comp liance was 88.2% (811 total participants, 5141 total cycles) with the patch and 77.7% (605 total participants, 4134 total cycles) with the OC (P <.001 ). Only 1.8% (300/16673) of patches completely detached. Both treatments we re similarly well tolerated; however, application site reactions, breast di scomfort, and dysmenorrhea were significantly more common in the patch grou p. Conclusion The contraceptive patch is comparable to a combination OC in con traceptive efficacy and cycle control. Compliance was better with the weekl y contraceptive patch than with the OC.